relebactam (Recarbrio) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Relebactum sodium (MK-7655) is a piperidine analog 3 that inhibits class A and C β-lactamases (in vitro). It is being investigated for use in treatment of infectious diseases, such as treatment of gram-negative bacterial infections. Its potential as an alternative to existing medicines in the treatment of drug-resistant bacterial infections is being studied. Clinical trials have been conducted and are still ongoing to evaluate the efficacy and safety of relebactum sodium in treatment of intra-abdominal infections, urinary tract infections (such as pyelonephritis), hospital-acquired and ventilator-associated bacterial pneumonias, and gram-negative bacterial infections.   NCATS

Chemistry

  • SMILES: OS(=O)(=O)ON1[C@@H]2CC[C@H](N(C2)C1=O)C(=O)NC3CCNCC3
  • InChIKey: SMOBCLHAZXOKDQ-ZJUUUORDSA-N
  • Mol. Mass: 348.38
  • ALogP: -1.14
  • ChEMBL Molecules:
    relebactam  
    relebactam  
More Chemistry

Pharmacology

Combination drugs

( cilastatin (primaxin), relebactam (Recarbrio), imipenem (primaxin) - other name: imipenem/cilastatin/relebactam )

Alternative names

mk-7655 | relebactam | relebactam anhydrous

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (2)


 

Pneumonia, Bacterial (approved 2020)

Urinary Tract Infections (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (17)


 

Bacterial Infections (Phase 4)

Carbapenems (Phase 4)

Communicable Diseases (Phase 1)

Critical Illness (Phase 4)

Cystic Fibrosis (Phase 4)

Gram-Negative Bacterial Infections (Phase 4)

Healthcare-Associated Pneumonia (Phase 3)

Intraabdominal Infections (Phase 2)

Lymphoma (Phase 2)

Neoplasms (Phase 2)

Obesity (Phase 4)

Pneumonia, Bacterial (Phase 4)

Pneumonia, Ventilator-Associated (Phase 3)

Pyelonephritis (Phase 2)

Sepsis (Phase 1)

Urinary Tract Infections (Phase 3)

Ventilators, Mechanical (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 16
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue